

#239

COMPLETE

Collector: Web Link 1 (Web Link)
Started: Tuesday, August 11, 2026 11:28:56 AM
Last Modified: Tuesday, August 11, 2026 11:41:06 AM
Time Spent: 00:12:10
IP Address: 24.207.17.170

Page 2: Part 1

Q1

Title of activity

CSACI ASM Hormones and Immunity: what every clinician should know about the female immune system

Q2

Date of activity

October 16th 2026

Q3

Speaker

What is your role in the CPD activity? (Select all that apply)

Q4

Community Practice

What's your practice type?

Q5

Please indicate:

I HAVE a relationship with a for-profit and/or a not-for-profit organization to disclose.If so, please indicate below (questions 5 to 10) the organization(s) with which you have/had a relationship over the previous two years and briefly describe the nature of that relationship.

Q6

Any direct financial payments including receipt of honoraria

Name of FOR PROFIT and/or NOT-for-profit organization(s)
(separate with commas)

Astellas, Bayer, Biosyent, Duchesnay, Lupin, Organon, Knight Therapeutics, Searchlight Pharma

Description of relationship(s)

Speaker

Q7

Membership on advisory boards or speakers' bureaus

Name of FOR PROFIT and/or NOT-for-profit organization(s)
(separate with commas)

**Astellas, Bayer, Biosyent, Duchesnay, Felix Health,
Lupin, Knight Therapeutics, Pause Collective**

Description of relationship(s)

Ad board member, consultant, program designer

Q8

Funded grants or clinical trials

Respondent skipped this question

Q9

Patents on a drug, product or device

Respondent skipped this question

Q10

All other investments or relationships that could be seen
by a reasonable, well-informed participant as having the
potential to influence the content of the educational activity

Respondent skipped this question

Page 3: Part 2: To be completed by presenters only

Q11

No

I intend to use trade names during my presentation. Note:
Only generic names should be used whenever possible. If
trade names are used, they should be accompanied by the
generic name.

Q12

I intend to make therapeutic recommendations for
medications that have not received regulatory approval
(i.e. "off-label" use of medication). Note: You must declare
all off-label use to the audience during your presentation.

Yes (please provide a brief description or rationale):
Use of off-label hormone therapy beyond guideline
recommendations as many have significant benefits beyond
them

Q13

Yes

If you answered "Yes" to the previous question, are the
medications recommended manufactured by companies
you have received funding from?

Q14

Yes

I acknowledge that the National Standard requires that any
description of therapeutic options utilize generic names (or
both generic and trade names) and not reflect exclusivity
and branding.

Page 4: Part 3 (Anonymous & Optional): Equity, Diversity and Inclusion (EDI)

Q15

Yes

I confirm that I've completed the EDI Survey linked above

Page 5: PART 4: Acknowledgement and signature (for all)

Q16

First Name:

Nathalie

Q17

Last Name:

Gamache

Q18

She/Her

Gender Pronouns - How would you like us to address you?

Q19

Please review and check the items below.

I confirm that the above information is accurate and complete.

,

I understand that this information may be publicly available
